Protocol Ledger

NCT06043427 · Phase II · RECRUITING

Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma

Interventional Phase II clinical trial protocol NCT06043427 sponsored by Canadian Cancer Trials Group in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-04-16 Enrollment: 168 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06043427
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)168 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06043427
Protocol FieldVerified Registry Value
NCT IdentifierNCT06043427
Consolidated Lead SponsorCanadian Cancer Trials Group
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment168 participants (ESTIMATED)
Registered Start Date2024-04-16
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06043427
Hospital Research SiteLocationSite Profile
Arthur J E Child Comprehensive Cancer CentreCalgary, CanadaOpen Hospital Dossier ->
CancerCare ManitobaWinnipeg, CanadaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI